WHO Pharmaceuticals Newsletter 2005, No. 05
(2005; 13 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoREGULATORY MATTERS
Cerrar esta carpetaSAFETY OF MEDICINES
Ver el documentoEstrogen/ progestin weekly patch - Higher levels of estrogen than birthcontrol pills
Ver el documentoFactor VIII (FVIII) recombinant products - Risk of inhibitor development in previously treated patients
Ver el documentoLiqiang 4 dietary supplement - Presence of glyburide
Ver el documentoMeningococcal vaccine - Reports of Guillain-Barré Syndrome
Ver el documentoMenze Qianweishu slimming herbs capsule - Found to contain sibutramine
Ver el documentoMethadone - Cardiac vigilance recommended
Ver el documentoNimodipine - Serious events due to IV use of oral formulations
Ver el documentoOseltamivir - Safety update
Abrir esta carpeta y ver su contenidoPROBLEMS OF CURRENT INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
 

Estrogen/ progestin weekly patch - Higher levels of estrogen than birthcontrol pills

USA. According to the US FDA, a weekly contraceptive skin patch (Ortho Evra) that releases ethinyl estradiol (an estrogen hormone) and norelgestromin (a progestin hormone), exposes women to higher levels of estrogen than most birth control pills. Since the patch is changed once a week, it decreases the risk of pregnancy associated with the typical birth control pills when a woman might miss one or more daily doses. However, this advantage should be considered in the light of the risks due to exposure to a higher level of estrogen with the patch. Women are advised to talk to their physician to see if the patch is the right birth control option for them.

Reference:

FDA News. United States Food and Drug Administration, 10 November 2005 (http://www.fda.gov).

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013